RE:RE:from the AGMEnriqueSuave ... That's my take. Everything points to th next indication. And GBM.
And as Patience69 accurately mentioned, stocks of TLD-1433 have already been produced for the NMIBC Ph. 2b. These things don't improvise at the last minute, as you have to prove shelf stability.
Theralase Demonstrates 36 Months Stability of Lead Anti-Cancer Drug announced today that it has demonstrated 36 months long term stability of the clinical batch of its lead anti-cancer PDC, TLD-1433. June 6, 2018 The confirmation of 36 months long term stability of TLD-1433 ensures that sufficient amounts of the PDC will be available at Good Manufacturing Practice (“GMP”) levels for multiple Photo Dynamic Therapy (“PDT”) patient treatments during the planned Phase 2 clinical study for Non-Muscle Invasive Bladder Cancer (“NMIBC”). Stability studies are an essential component of pharmaceutical development, allowing evaluation of a drug’s stability under the influence of a variety of environmental factors such as: temperature, humidity and light. Data from these studies enable recommended: storage conditions, retest intervals and shelf life to be established.
Demonstrating long term stability of a drug to be used in human clinical testing is essential to prove that the potency and/or efficacy of the drug is not affected during prolonged shelf life.
_______________
enriquesuave - (12/3/2019 9:31:44 AM) RE:from the AGM it could be for making Rutherrin. TLD-1433 still from original manufacturers but new company to prepare the mix?
_______________
patience69 - (12/3/2019 9:08:51 AM) from the AGM Pretty sure that Claridge is correct. I do recall at the question period at the AGM regarding upcoming expenses they said that they had enough 1433 for phase 2. There would be no more purchases of drug necessary for the entire study. It had been bought & paid for . If this is purchase of a compund it must be for the next indication. Bring it on. Tomorrow would be fine!